Abemaciclib-induced myocarditis in early breast cancer: a case report
Abstract Background Abemaciclib, a selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, is standard adjuvant therapy for hormone receptor (HR)-positive, HER2-negative early breast cancer. While gastrointestinal and haematologic toxicities are well recognised, cardiotoxicity—particularly myo...
Gorde:
| Egile Nagusiak: | , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BMC
2026-01-01
|
| Saila: | Cardio-Oncology |
| Gaiak: | |
| Sarrera elektronikoa: | https://doi.org/10.1186/s40959-025-00442-2 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|